Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2006

View Archived Issues

Medicure makes productive start to FY2007

Genzyme offers progress report for third quarter

Taisho presents prodrug of antidepressant and anxiolytic agent MGS-0039

PDL BioPharma and ECCO collaborate to support visilizumab program

Adventrx licenses ANX-211 to Theragenex

Starpharma completes acquisition of Dendritic Nanotechnologies

Zenyth shareholders approved CSL acquisition proposal

Lytix seeks to outlicense SAMPs

Connetics and Stiefel Laboratories sign definitive merger agreement

Pivotal study of Efaproxyn cleared to continue to final analysis

ChondroGene changes name to GeneNews

AV-412 begins clinical trials

Second phase III trial of Mozobil completes enrollment

Phase I study of GlycoPEG-GCSF cleared to begin in Western Europe

Data on phenylalanine reduction with sapropterin reported

Losartan may benefit Duchenne muscular dystrophy, Marfan syndrome patients

Two phase III studies of MK-0518 in HIV infection under way

Abbott profiles novel 5-HT5A receptor antagonist candidates

Recent patents report novel therapeutic agents for Alzheimer's disease

Novel agents for HIV infection patented

Recent patents cover possible novel treatment options for diabetes and associated disorders

Inhibition of oncogenic FoxM1 by siomycin A: A new anticancer strategy

Pfizer presents novel PDE10 inhibitors as potential antipsychotics

Preclinical data support repositioning propranolol from hypertension to Alzheimer's disease

NPY Y5 antagonist radioligands from Merck & Co., useful to characterize Y5 brain distribution

Seroquel approved for depressive episodes associated with bipolar disorder

Noxafil approved for treatment of oropharyngeal candidiasis

New Nexium formulation approved by FDA

Requip approved in Japan for Parkinson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...